Fashioning Growth and Precision with Digitally-Native Fabletics
Digitally-native activewear startup Fabletics was founded in 2013
Company has grown revenue 30% annually, now approaching $900 million and is profitable
Employs a unique VIP membership model that is free with big discounts, other perks
VIP program helps Fabletics command a loyal following and precise inventory forecasting
Plans to double store count to 200 by 2030 including international additions
By
In the old days, apparel retailers had no choice but to make risky bets when it came to forecasting customer demand. But in the new age of digitally-native brands, the smartest players can lean on data from a new generation of loyalty programs to remove most of the guesswork – making both customers and investors happier.
One such company to watch is privately-held activewear pioneer Fabletics, which was founded in 2013 with a focus on fashion-forward designs and performance technology. The company is profitable and has grown to top line consistently at 30% annually, approaching $900 million in annual revenue. Success has been driven by strength in its core women's division along with newer, high-growth categories such as men's along with medical scrubs.
Fabletics, led by successful entrepreneur and CEO Adam Goldenberg, stands out as a company that cultivated a brand in a purely digital setting before opening its first physical store. Mr. Goldenberg brings a serious track record to the table: Working with Fabletics co-founder Don Ressler, he has generated over $10 billion in sales through TechStyle Fashion Group, which launched digitally native fashion brands Savage X Fenty, JustFab, ShoeDazzle, FabKids, and Yitty – in addition to Fabletics.
One unique feature of Fabletics is a membership model that benefits both the company and its customers. It's free to be a VIP member, which includes benefits such as 20%-30% off all purchases, exclusive offerings, access to thousands of workouts on the FIT app and more. In return, the company gets to collect valuable data around sizes, frequency of purchases, and style preferences. Over 70 billion data records are processed annually with 80% of customers always shopping logged-in as members.
The VIP program not only creates loyalty and engagement, but precise inventory predictability. Fabletics boasts 95% accuracy in sizing and demand forecasting with inventory informed by member sizes and preferences. That translates to less than 1% inventory obsolescence and an industry-leading return and exchange rate of just 7%.
Fabletics also offers VIP members the chance to buy $100 in credits for only $59.95 each month, but it's not required. Members can simply toggle the feature off at the start of any given month and won't be charged but still enjoy all other VIP benefits.
For context, even big and sophisticated retailers struggle with forecasting and inventory planning. Take Lululemon Athletica, which has multiple high-profile stumbles with inventory over the years. As recently as last year, Lululemon had to cut sales guidance in part due to missteps in product strategy and execution.
Fabletics can also be very deliberate about its brick-and-mortar expansion. While traditional retailers often targeted several hundred or even thousands of stores, Fabletics is much more deliberate. The company has over 100 stores and plans to gradually double to about 200 by 2030.
Data also helps with location selection. Fabletics knows where its best shoppers are located and can choose locations with real information – again removing much of the guesswork.
The company, which has posted same-store sales of 20% or more recently, has its sights on new territories. It announced its expansion into Mexico through a partnership with omnichannel retail group Liverpool, which will operate retail, fabletics.com.mx and wholesales operations – beginning in the second quarter. It will also explore expansion into additional regions like Central America, South America, Australia and the Middle East.
Fabletics has a rare combination of loyal customers, the tech to track them and a track record of near-flawless execution. While the company remains private for now, investors following retailers should keep a close eye on this trailblazer.
Contact:
executives-edge.com
Editor@executives-edge.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 hours ago
- Yahoo
Fabletics Elevates Key Leaders as It Eyes $1 Billion Milestone
Fabletics has announced two key executive leadership Bhatia, who previously served as chief operating officer, has been elevated to president and COO. She has driven initiatives across e-commerce, production, operations and technology, while leading the brand's expansion into new channels. Her role now spans product creation, retail, wholesale and international Gomez, formerly senior vice president of brand marketing, is now chief marketing officer. She will lead all brand, digital innovation and customer engagement initiatives. According to Fabletics, Gomez has been leveraging customer insights to inform impactful marketing in 2013 and headquartered in El Segundo, Calif., the activewear brand operates on a membership-based model rooted in e-commerce and supported by a growing number of retail stores. Owned by TechStyle Fashion Group, Fabletics is on track to exceed $1 billion in revenue, according to Adam Goldenberg, Fabletics' cofounder and chief executive officer. He, Bhatia and Gomez have worked closely to guide the company's growth.'We're introducing new store formats and pursuing plans for international expansion — all while continuing to deliver the innovative partnerships and best-in-class product we are known for,' said Goldenberg in a statement. 'We are thrilled to have Meera and Carly expand their roles and position us for continued success.''I am honored to assume the roles of president and COO at Fabletics during a time of immense growth and international expansion,' said Bhatia. 'Fabletics is a driving force in an evolving activewear industry, leading from design, product, technology and community. I look forward to helping lead the brand to new heights in my new role.''I joined Fabletics last year because I believe it is at the cutting edge of customer engagement, and is truly reinventing the activewear space,' said Gomez. 'Stepping into the CMO role, I am excited to unlock new ways of elevating our brand and delivering an impactful customer experience that propels Fabletics forward in this next chapter.' More from WWD David Beckham Launches Beeup, Honey Fruit Gummies, With Shaun Neff Tracy Anderson Introduces New Studio Concept in Santa Monica: Privé Kathy Gohari Named President of Rodeo Drive Committee Best of WWD Kate Middleton's Looks at Trooping the Colour Through the Years [PHOTOS] Young Brooke Shields' Style Evolution, Archive Photos: From Runway Modeling & Red Carpets to Meeting Princess Diana The Most Memorable French Open Tennis Outfits With Serena Williams, Naomi Osaka & More [PHOTOS]
Business Wire
3 days ago
- Business Wire
SunRock Biopharma and Escugen Forge Alliance to Develop First-in-Class CCR9-Targeted ADC
SANTIAGO DE COMPOSTELA, Spain & SHANGHAI--(BUSINESS WIRE)--SunRock Biopharma and Escugen have joined forces in a strategic partnership to co-develop SRB123, a First-in-Class antibody-drug conjugate (ADC) targeting C-C motif chemokine receptor 9 (CCR9), a tumor-associated antigen overexpressed in multiple solid tumors, including pancreatic, ovarian and lung cancer. SunRock Biopharma and Escugen have entered a strategic partnership to co-develop SRB123, a first-in-class antibody-drug conjugate targeting CCR9, a tumor-associated antigen overexpressed in pancreatic, ovarian and lung cancers Share The collaboration combines SunRock's proprietary SRB1 antibody, selected for its high binding affinity and efficient tumor cell internalization, with Escugen's EZWi-Fit™ linker-payload platform, a next-generation ADC technology optimized for the linker stability and selective tumor release of the potent payload. The result is a highly differentiated therapeutic candidate designed exclusively for solid tumors with high CCR9 expression and internalization rates. Under the agreement, both companies will share development responsibilities, file joint patents, and hold reciprocal licensing option rights. The primary goal is to generate robust preclinical proof-of-concept data to support early clinical entry in the near term. 'Combining our deep antibody engineering expertise with Escugen's innovative conjugation platform enables us to deliver a precision oncology candidate with First-in-Class potential,' said Dr. Laureano Simón, CEO of SunRock. 'CCR9 remains an underexploited but clinically validated target. This program addresses real unmet needs in aggressive tumors with poor prognosis.' Dr. Qing Zhou, Co-Founder and CEO of Escugen, stated, 'This strategic collaboration with SunRock Biopharma aligns with our vision of developing First-in-Class precision oncology candidates through technological innovation. It further highlights the unique advantages of our EZWi-Fit™ platform technology in next-generation ADC development. The platform's strong anti-tumor activity and favorable tolerability provide a solid foundation for targeting high CCR9-expressing solid tumors. We are confident that combining our expertise will accelerate SRB123's progress and bring new hope to patients.' CCR9 has been associated with metastatic potential and chemoresistance, particularly in pancreatic and ovarian cancers. SRB1, the unconjugated antibody from SunRock, has already demonstrated strong preclinical efficacy in these models. The ADC format (SRB123) leverages this targeting while enhancing tumor cell killing via Escugen's payload delivery system. The partnership will be showcased during the BIO International Convention 2025, where both companies will engage with potential development and commercialization partners. About SunRock Biopharma SunRock Biopharma is a biotech company focused on developing next-generation antibody-based therapies targeting unmet medical needs in oncology and immunology. Operating under an open innovation model, SunRock combines cutting-edge academic science, advanced technology platforms, and a selective business approach to generate highly differentiated, licensable assets. Its portfolio includes optimized monoclonal antibodies, next-generation ADCs, and radioconjugates, with validated targets such as CCR9 and HER3. SunRock follows an early-stage out-licensing strategy, designed to maximize risk-adjusted returns, and maintains active collaborations with leading pharma and biotech partners worldwide. About Escugen Escugen is a clinical-stage biotechnology company located in Shanghai, China, focusing on the development of innovative ADC drugs. Currently, Escugen's lead Trop-2 ADC pipeline, ESG401, has entered Phase III clinical trials. Escugen's next-generation linker-payload technology platform, EZWi-Fit®, offers significant competitive advantages in terms of safety, efficacy, anti-multiple drug resistance, and pharmacokinetic characteristics. Leveraging this platform technology, Escugen is rapidly expanding its ADC pipeline targeting new or validated target. The first ADC product baring the EZWi-Fit® technology has successfully launched its FIH clinical campaign. In addition, Escugen has licensed this platform technology to several domestic and international biotechnology companies to empower their innovative ADC projects.
Yahoo
7 days ago
- Yahoo
Is American billionaire funding LA, pro-Palestine campus protests?
(NewsNation) — The Trump administration and Republican lawmakers are launching an investigation into who is providing funding for anti-ICE protests that are taking place in Los Angeles as well as campus pro-Palestine demonstrations that have taken place across the country. That has led the FBI and IRS to American billionaire Neville Roy Singham, who is currently living in Shanghai. Members of the House Oversight Committee have told NewsNation that Singham will be called to testify before the committee about his ties to the Chinese Communist Party as well as his funding of anti-Israel groups and his connections to other groups that are believed to be behind the Los Angeles protests. After US-Iran nuclear talks crumble, what happens next? NewsNation has found that Singham sold his company in 2017 for close to $1 billion, and reports indicate that Singham has since provided funding to groups such as the People's Forum. The organization, which is based in New York City, also has ties to the Party for Socialism and Liberation, a communist political party that is said to be behind the large-scale, anti-ICE protests that are taking place in Los Angeles. Alex Goldenberg, a senior adviser with the Network Contagion Research Institute, told NewsNation that Singham has a footprint in India, South Africa and London and remains active in the United States. Goldenberg said that Singham is funding a large network of nonprofit groups, providing them with tens of millions of dollars. 'He's not just funding activism. What we find is that he is funding and exporting an authoritarian-aligned ideology under the banner of American nonprofit legitimacy,' he said. Goldenberg said that in addition to pushing anti-American sentiments, the groups allegedly funded by Singham promote and glorify terrorism and violent revolutions. 'What is being built here is not a protest movement,' Goldenberg told NewsNation. 'I really view it as infrastructure for a deeply un-American campaign to destabilize the country from within.' Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
